Research ArticleConference Proceedings
PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications
Stephan Krause, Emanuela Lacana, Joel Welch, Marjorie Shapiro, Christopher Downey, Jee Chung, Qing Zhou, Martijn Van Der Plas, Chantal Depatie, Bev Ingram, Catherine Srebalus-Barnes, Alla Polozova, Barbara Rellahan, Daeseok Choi, Richard Burdick, Thomas Stangler and Emily Shacter
PDA Journal of Pharmaceutical Science and Technology July 2019, 73 (4) 401-416; DOI: https://doi.org/10.5731/pdajpst.2019.010215
Stephan Krause
1AstraZeneca Biologics, 1 Medimmune Way, Gaithersburg, MD 20878;
Emanuela Lacana
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
Joel Welch
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
Marjorie Shapiro
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
Christopher Downey
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
Jee Chung
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
Qing Zhou
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
Martijn Van Der Plas
3Medicines Evaluation Board (MEB), Graadt van Roggenweg 500, 3531 AH Utrecht, The Netherlands;
Chantal Depatie
4Health Canada, 100 Eglantine Driveway, Ottawa, ON K1A 0K9, Canada;
Bev Ingram
5Pfizer Inc., 1 Burtt Road, Andover, MA 01810;
Catherine Srebalus-Barnes
6Pfizer Inc., 275 North Field Drive, Lake Forest, IL 60045;
Alla Polozova
7Amgen Inc., 360 Binney Street, Cambridge, MA 02142;
Barbara Rellahan
8Amgen, Inc., 601 13th Street, NW, Suite 1100 North, Washington, DC 20005;
Daeseok Choi
9CELLTRION Inc., 19, Academy-ro 51, Yeonsu-gu, Incheon 406-840, Republic of Korea;
Richard Burdick
10Burdick Statistical Consulting, LLC, 7783 Renegade Hill Drive, Colorado Springs, CO 80923;
Thomas Stangler
11Novartis, Biochemiestraße 10, 6336 Langkampfen, Austria; and
Emily Shacter
12ThinkFDA, LLC, 710 Erie Ave, Takoma Park, MD 20912

References
- 1.Health Canada Guidance Document: Information and submission requirements for biosimilar biologic drugs, December 2016. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/information-submission-requirements-biosimilar-biologic-drugs.html.
- 2.FDA Guidance for Industry: Data Integrity and Compliance with Drug CGMP, December 2018.
- 3.US Code of Federal Regulations, Title 21, Part 11.
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 73, Issue 4
July/August 2019
PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications
Stephan Krause, Emanuela Lacana, Joel Welch, Marjorie Shapiro, Christopher Downey, Jee Chung, Qing Zhou, Martijn Van Der Plas, Chantal Depatie, Bev Ingram, Catherine Srebalus-Barnes, Alla Polozova, Barbara Rellahan, Daeseok Choi, Richard Burdick, Thomas Stangler, Emily Shacter
PDA Journal of Pharmaceutical Science and Technology Jul 2019, 73 (4) 401-416; DOI: 10.5731/pdajpst.2019.010215
PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications
Stephan Krause, Emanuela Lacana, Joel Welch, Marjorie Shapiro, Christopher Downey, Jee Chung, Qing Zhou, Martijn Van Der Plas, Chantal Depatie, Bev Ingram, Catherine Srebalus-Barnes, Alla Polozova, Barbara Rellahan, Daeseok Choi, Richard Burdick, Thomas Stangler, Emily Shacter
PDA Journal of Pharmaceutical Science and Technology Jul 2019, 73 (4) 401-416; DOI: 10.5731/pdajpst.2019.010215
Jump to section
- Article
- Abstract
- P1: Regulatory Perspective on Biosimilar Marketing Applications
- Regulatory Perspective on Biosimilar Marketing Applications
- Evolving EU Views on Analytical Similarity
- A Reviewer's Perspective of Biosimilar Submissions
- P1: Summary of Concurrent Breakout Roundtable Discussions
- P1: Panel Discussion
- The Trapeze and the Trap Door: Navigating High-Level Technical Challenges in Biosimilar Development
- Data Quality Considerations for Biosimilar Development
- Key Lessons Learned from Navigating the Challenges Associated with Biosimilar Product Development
- A Systematic Approach to Establish a Manufacturing Control Strategy in Biosimilar Development: A Regulatory Perspective
- P2: Summary of Panel Question and Answer Session
- P2: Summary of Concurrent Breakout Roundtable Discussions
- P2: Panel Discussion
- Moderator: Joel T. Welch, PhD, Review Chief, CDER, FDA
- P2: Summary of Concurrent Breakout Sessions
- P3: Demonstrating Analytical Similarity: The Role of Statistical Tools
- Reflections on Comparability (Similarity) and Methodology
- Statistical Tools for Demonstrating Analytical Similarity: Range Test, Equivalence Test of Means, and Distribution Comparisons
- Performance Characteristics of Commonly Used Statistical Approaches in the Evaluation of Analytical Similarity
- P3: Summary of Panel Question and Answer Session
- P3: Summary of Concurrent Breakout Roundtable Discussions
- P3: Panel Discussion
- Conflict of Interest Declaration
- Abbreviations
- References
- References
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- No citing articles found.